GEORGE SIMEON sold 48.4% of their position (14.51K shares) of CRISPR THERAPEUTICS AG on the open market
Open‑market sale worth $720.4K — a major position exit. Review remaining holdings and any 10b5‑1 plan disclosures.
S · 1 sale
Filed: 10/16/2026ACC: 0001193125-26-424317
-14.51K
Net shares
Net seller
$720.4K
Total sold
1
Open market trades
0B · 1S
3
Total transactions
30K acquired · 44.51K disposed
Non-Derivative Transactions2
Common Shares
Direct
Shares
+30K
Price / share
$14.00
Trade value
$420K
% of position
New position
10/14/2026
0.00→30K
Common Shares
Direct
Shares
−14.51K
Price / share
$49.63
Trade value
$720.37K
% of position
48.4%
10/14/2026
30K→15.49K
Total
Net shares
+15.49K
Net value
-$300.37K
| Security | Date | Type | Shares | Price / Share | Trade Value | % of Position | Held Before | Held After |
|---|---|---|---|---|---|---|---|---|
| Common Shares Direct | 10/14/2026 | M · Option Exercise | +30K | $14.00 | $420K | New position | 0.00 | 30K |
| Common Shares Direct | 10/14/2026 | S · Sale | −14.51K | $49.63 | $720.37K | 48.4% | 30K | 15.49K |
| Total | +15.49K | -$300.37K | ||||||
Derivative Transactions1
Stock Option (Right to Buy)
Direct
Converts to
Common Shares
30K shares
Shares
−30K
Strike price
14
Held after
0.00
Exercisable
—
10/14/2026
| Security | Converts To | Date | Type | Shares | Strike Price | Exercisable | Held After |
|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy) Direct | Common Shares30K shares | 10/14/2026 | M · Option Exercise | −30K | 14 | — | 0.00 |
Non-Derivative Holdings (Post-Transaction)3
Common Shares
IndirectShares owned69.69K
Common Shares
IndirectShares owned1.73M
Common Shares
IndirectShares owned238.90K
Total
2.04M indirect2.04M
| Security Title | Shares Owned | Ownership Type |
|---|---|---|
| Common Shares | 69.69K | Indirect |
| Common Shares | 1.73M | Indirect |
| Common Shares | 238.90K | Indirect |
| Total | 2.04M | 2.04M indirect |
Derivative Holdings (Post-Transaction)0
No derivative holdings reported